A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT
AUTOR(ES)
Gommerman, Jennifer L.
FONTE
American Society for Clinical Investigation
RESUMO
In studies using genetically deficient mice, a role for the lymphotoxin (LT) system in the pathogenesis of experimental autoimmune encephalomyelitis (EAE) has remained controversial. Here, we have reassessed this conclusion by using a fusion protein decoy that blocks the LT pathway in vivo without evoking the developmental defects inherent in LT-deficient mice. We have found that inhibition of the LT pathway prevented disease in two models of EAE that do not rely on the administration of pertussis toxin. Surprisingly, disease attenuation was due to specific blockade of LTαβ binding rather than the binding of LIGHT to its receptors. In a third system that requires pertussis toxin, LT inhibition did not affect disease, as was observed when the same model was used with LT-deficient mice. Disease prevention in pertussis toxin–free models was associated with defects in T cell responses and migration. When the DO11.10 T cell transgenic system was used, inhibition of the LT pathway was shown to uncouple T cell priming from T cell recall responses. Therefore, it is hypothesized that the LT pathway and its ability to maintain lymphoid microenvironments is critical for sustaining late-phase T cell responses in multiple sclerosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=182210Documentos Relacionados
- CD28-independent induction of experimental autoimmune encephalomyelitis
- Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis
- Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis
- Participação das células dendríticas plasmocitóides na esclerose múltipla e na encefalomielite autoimune experimental = : Role of plasmacytoid dendritic cells in multiple sclerosis and in experimental autoimmune encephalomyelitis
- A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis